Missouri Patent of the Month – February 2021
Following medical procedures, blood loss is a common concern. Controlling bleeding is done by electrocautery, suturing, stapling, or even pressure application. Arteries are quite sensitive however, and require a time commitment to provide pressure until the body is able to close the opening itself. Some methods involving hemostatic agents and sealants are also in use, to block or close the artery tissue manually. MediBeacon, Inc. has been working on the development of a tissue sealant to help close arterial tissue with agents that make it easy to see as it is implemented.
Their method utilizes a sealant that incorporates an optical dye. These dyes change colour or fluorescence as they begin to change into a seal or clot, thereby closing the open wound.. These changes provide easy optical confirmation that the wound is sealing, and will reduce the risk of blood loss.
MediBeacon is a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement. Their fluorescent agent platform is used in physiological function monitoring and has important applications in kidney health, gastrointestinal health, and beyond.
Are you developing new technology ? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.